Drugs / sodium aescinate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07339631 | Mar 2026 → Sep 2029 expected | — | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05263167 | Mar 2022 → Dec 2024 | brain edema | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04247659 | Jan 2020 → Jun 2021 | brain edema, cerebral infarction | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium aescinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04247659 ↗ |
| Known as | Sodium Aescinate Tablets | “Drug: Sodium Aescinate Tablets” NCT07339631 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04247659 ↗ |